Regeneron Pharmaceuticals Inc on Thursday said it has begun human testing of its experimental antibody cocktail as a treatment for COVID-19, the disease caused by the novel coronavirus.
The trial has an "adaptive" design and could quickly move from dozens of patients to eventually include thousands, Chief Scientific Officer George Yancopoulos told Reuters.
The dual antibody, called REGN-COV2, is being compared to a placebo treatment in hospitalized COVID-19 patients, and in COVID-19 patients who have symptoms but are not sick enough to be hospitalized. Antibodies are proteins made by the body's immune system that recognize, bind and neutralize an invading virus.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eastern Visayas 'alarmed' over highest single-day rise in COVID-19 cases with 19 new patientsThe Health Department in Eastern Visayas expressed concern on Wednesday as the region hit its highest single-day surge in COVID-19 cases, listing 19 new infections.
Read more »
Human trial begins in China on another potential COVID-19 antibody therapyDoctors dosed a healthy volunteer with an antibody treatment developed by Eli Lilly and Chinese company Junshi Biosciences to fight COVID-19
Read more »
NJLA ‘indefinitely deferred’ due to COVID-19The Nick Joaquin Literary Awards (NJLA) and the Nick Joaquin Literary Awards Asia-Pacific for 2020 have been indefinitely deferred due to the COVID-19 pandemic, Philippines Graphic announced on June 9, Tuesday.
Read more »
FALSE: Bill Gates is developing COVID-19 vaccines with microchipsFactCheck: There are no reports on studies being done on a COVID-19 vaccine with a microchip; Bill Gates has also denied the claim.
Read more »
13 new cases of COVID-19 in Lucena CityThe City Health Office (CHO) here reported that there were 13 new coronavirus disease (COVID-19) cases here in just a matter of 24 hours, bringing the total cases of 61 and 32 recoveries, as of 9 p.m. Tuesday.
Read more »